Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women

Journal of Clinical Oncology

Volumn 16, Issue 10, 1998, Pages 3439-3460

  Fossati, R ^a   Confalonieri, C ^a   Torri, V ^a   Ghislandi, E ^a   Penna, A ^a   Pistotti, V ^a   Tinazzi, A ^a   Liberati, A ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MEDROXYPROGESTERONE; MEGESTROL; METHOTREXATE; TAMOXIFEN; VINBLASTINE; VINCRISTINE;

ALOPECIA; BODY WEIGHT DISORDER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; WEIGHT GAIN;

EID: 0031759089     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.10.3439     Document Type: Review

References (213)

1. Pisani P, Parkin DM, Ferlay J: Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 55:891-903, 1993
2. Hayes DF, Kaplan W: Evaluation of Patients Following Primary Therapy. Philadelphia, PA, Lippincott, 1991, pp 505-525
3. Hayes DF, Henderson IC, Shapiro CL: Treatment of metastatic breast cancer: Present and future prospects. Semin Oncol 22:5-21, 1995 (suppl 5)
4. Hortobagyi GN, Piccart-Gebhart MJ: Current management of advanced breast cancer. Semin Oncol 23:1-5, 1996 (suppl 11)
5. Smith G, Henderson IC: New treatments for breast cancer. Semin Oncol 23:506-528, 1996
6. Howell A, Dowsett M: Recent advances in endocrine therapy of breast cancer. BMJ 315:863-866, 1997
7. Parmar MKB, Machin D: Survival Analysis: Practical Approach. Chichester, United Kingdom, Wiley, 1995
8. Parmar MKB, Torri V, Stewart LA: Extraction of summary statistics to perform meta-analysis of the published literature for survival endpoints. Stat Med (in press)
9. Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307-310, 1986
10. Early Breast Cancer Trialists' Collaborative Group: Treatment of Early Breast Cancer, vol 1. Worldwide Evidence 1985-1990. Oxford, United Kingdom, Oxford University, 1990
11. Rubens RD, Knight RK, Hayward JL: Chemotherapy of advanced breast cancer: A controlled randomized trial of cyclophosphamide versus a four-drug combination. Br J Cancer 32:730-736, 1975
12. Canellos GP, Pocock SJ, Taylor SG, et al: Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer 38:1882-1886, 1976
13. Hoogstraten B, George SL, Samal B, et al: Combination chemotherapy and Adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study. Cancer 38:13-20, 1976
14. Mouridsen HT, Palshof T, Brahm M, et al: Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rep 61:47-50, 1977
15. Carmo-Pereira J, Oliveira Costa F, Henriques E: Single-drug vs combination cytotoxic chemotherapy in advanced breast cancer: A randomized study. Eur J Cancer 16:1621-1625, 1980
16. Steiner R, Stewart JF, Cantwell BMJ, et al: Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol 19:1553-1557, 1983
17. Ingle JN, Green SJ, Brunk SF, et al: Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast cancer and prior chemotherapy exposure. Am J Clin Oncol 8:275-282, 1985
18. Andersson M, Daugaard S, von der Maase H, et al: Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: A randomized study. Cancer Treat Rep 70:1181-1186, 1986
19. Gundersen S, Kvinnsland S, Klepp O, et al: Weekly Adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol 22:1431-1434, 1986
20. Ahmann DL, Schaid DJ, Bisel HF, et al: The effect on survival of initial chemotherapy in advanced breast cancer: Polychemotherapy versus single drug. J Clin Oncol 5:1928-1932, 1987
21. Vaughn CB, Green SJ, O'Bryan R, et al: VP-16 + Adriamycin vs. Adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial: A Southwest Oncology Group study. Med Pediatr Oncol 16:312-319, 1988
22. Ingle JN, Mailliard JA, Schaid DJ, et al: Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer. Am J Clin Oncol 12:474-480, 1989
23. Nielsen D, Dombernowsky P, Skovsgaard T, et al: Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III study. Ann Oncol 1:275-280, 1990
24. French Epirubicin Study Group: A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 9:305-312, 1991
25. Fraser SCA, Dobbs HJ, Ebbs SR, et al: Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life. Br J Cancer 67:402-406, 1993
26. De Lena M, Brambilla C, Morabito A, et al: Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer. Cancer 35:1108-1115, 1975
27. Brambilla C, De Lena M, Rossi A, et al: Response and survival in advanced breast cancer after two non-cross-resistant combinations. BMJ 1:801-804, 1976
28. Bull JM, Tormey DC, Li SH, et al: A randomized comparative trial of Adriamycin versus methotrexate in combination drug therapy. Cancer 41:1649-1657, 1978
29. Muss HB, White DR, Richards F, et al: Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. A randomized trial. Cancer 42:2141-2148, 1978
30. Bezwoda WR, De Moor NG, Derman D, et al: Combination chemotherapy of metastatic breast cancer. A randomized trial comparing the use of Adriamycin to that of vinblastine. Cancer 44:392-397, 1979
31. Creech RH, Catalano RB, Harris DT, et al: Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, Adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and Adriamycin. Cancer 43:51-59, 1979
32. Carmo-Pereira J, Oliveira Costa F, Henriques E: Chemotherapy of advanced breast cancer: A randomized trial of vincristine, Adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP). Cancer 48:1517-1521, 1981
33. Muss HB, Richards F, Jackson DV, et al: Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer. Cancer 50:2269-2274, 1982
34. Tormey DC, Gelman R, Band PR, et al: Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group trial. Cancer 50:1235-1244, 1982
35. Smalley RV, Lefante J, Bartolucci A, et al: A comparison of cyclophosphamide, Adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat 3:209-220, 1983
36. Creagan ET, Green SJ, Ahmann DL, et al: A phase III clinical trial comparing the combination cyclophosphamide, Adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer. J Clin Oncol 2:1260-1265, 1984
37. Tormey DC, Weinberg VE, Leone LA, et al: A comparison of intermittent vs. continuous and of Adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. Am J Clin Oncol 7:231-239, 1984
38. Cummings FJ, Gelman R, Horton J: Comparison of CAF versus CMFP in metastatic breast cancer: Analysis of prognostic factors. J Clin Oncol 3:932-940, 1985
39. Parvinen LM, Numminen S: Chemotherapy in advanced breast carcinoma. Comparison between doxorubicin-cyclophosphamide and cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisolone. Acta Radiol Oncol 24:391-394, 1985
40. Aisner J, Weinberg V, Perloff M, et al: Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each ± MER) for metastatic carcinoma of the breast: A CALGB study. J Clin Oncol 5:1523-1533, 1987
41. Leonard RCF, Cornbleet MA, Kaye SB, et al: Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast. J Clin Oncol 5:1056-1063, 1987
42. Bennett JM, Muss HB, Doroshow JH, et al: A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 6:1611-1620, 1988
43. Rosner D, Lane WW, Nemoto T: Differential response to chemotherapy in metastatic breast cancer in relation to estrogen receptor level. Results of a prospective randomized study. Cancer 64:6-15, 1989
44. Cocconi G, Bisagni G, Bacchi M, et al: A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol 1:36-44, 1990
45. Heidemann E, Steinke B, Hartlapp J, et al: Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. Onkologie 13:24-27, 1990
46. Porzsolt F, Kreuser ED, Meuret G, et al: High-intensity therapy versus low-intensity therapy in advanced breast cancer patients. Cancer Treat Rev 17:287-292, 1990
47. Ahmann DL, Schaid DJ, Ingle JN, et al: A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer. Am J Clin Oncol 14:179-183, 1991
48. Falkson G, Tormey DC, Carey P, et al: Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer. Eur J Cancer 27:973-977, 1991
49. Periti P, Pannuti F, Della Cuna GR, et al: Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: A comparative randomized multicenter study in metastatic breast carcinoma. Cancer Invest 9:249-255, 1991
50. Powles TJ, Jones AL, Judson IR, et al: A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. Br J Cancer 64:406-410, 1991
51. Smith IE, Powles TJ: MMM (mitomycin/mitoxantrone/methotrexate): An effective new regimen in the treatment of metastatic breast cancer. Oncology 50:9-15, 1993 (suppl 1)
52. Alonso MC, Tabernero JM, Ojeda B, et al: A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Breast Cancer Res Treat 34:15-24, 1995
53. Hausmaninger H, Lehnert M, Steger G, et al: Randomized phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer. Eur J Cancer 31A:2169-2173, 1995
54. Pavesi L, Preti P, Da Prada G, et al: Epirubicin versus mitoxantrone in combination chemotherapy for metastatic breast cancer. Anticancer Res 15:495-502, 1995
55. Green JA, Slater AJ, Campbell IR, et al: Advanced breast cancer: A randomized study of doxorubicin or mitoxantrone in combination with cyclophosphamide and vincristine. Breast Cancer Res Treat 39:155-163, 1996
56. Segaloff A, Hankey BF, Carter AC, et al: An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone in advanced breast cancer. Breast Cancer Res Treat 5:311-319, 1985
57. Marschke RF, Ingle JN, Schaid DJ, et al: Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer. Cancer 63:1931-1937, 1989
58. Cocconi G, Bisagni G, Bacchi M, et al: Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: A prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 9:664-669, 1991
59. Jodrell DI, Smith IE, Mansi JL, et al: A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer. Br J Cancer 63:794-798, 1991
60. Yosef H, Slater A, Keen CW, et al: Prednimustine (Sterecyt) versus cyclophosphamide both in combination with methotrexate and 5-fluorouracil in the treatment of advanced breast cancer. Eur J Cancer 29A:1100-1105, 1993
61. Hainsworth JD, Jolivet J, Birch R, et al: Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma. A randomized phase II trial. Cancer 79:740-748, 1997
62. Jain KK, Casper ES, Geller NL, et al: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3:818-826, 1985
63. Brambilla C, Rossi A, Bonfante V, et al: Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 70:261-266, 1986
64. French Epirubicin Study Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6:679-688, 1988
65. Italian Multicentre Breast Study With Epirubicin: Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial. J Clin Oncol 6:976-982, 1988
66. Hortobagyi GN, Yap HY, Kau SW, et al: A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol 12:57-62, 1989
67. Lopez M, Papaldo P, Di Lauro L, et al: 5-Fluorouracil, Adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophospamide (FEC) in metastatic breast cancer. Oncology 46:1-5, 1989
68. Gundersen S, Kvinnsland S, Klepp O, et al: Weekly Adriamycin vs. 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial. Eur J Cancer 26:45-48, 1990
69. Gasparini G, Dal Fior S, Panizzoni GA, et al: Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial. Am J Clin Oncol 14:38-44, 1991
70. Perez DJ, Harvey VJ, Robinson BA, et al: A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 9:2148-2152, 1991
71. Forastiere AA, Hakes TB, Wittes JT, et al: Cisplatin in the treatment of metastatic breast carcinoma. A prospective randomized trial of two dosage schedules. Am J Clin Oncol 5:243-247, 1982
72. Carmo-Pereira J, Oliveira Costa F, Henriques E, et al: A comparison of two doses of Adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 56:471-473, 1987
73. Hortobagyi GN, Bodey GP, Buzdar AU, et al: Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: A prospective randomized study J Clin Oncol 5:354-364, 1987
74. Tannock IF, Boyd NF, DeBoer G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377-1387, 1988
75. Ebbs SR, Saunders JA, Graham H, et al: Advanced breast cancer. A randomised trial of epidoxorubicin at two different dosages and two administration systems. Acta Oncol 28:887-892, 1989
76. Harris AL, Cantwell BMJ, Carmichael J, et al: Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet 335:186-190, 1990
77. Engelsman E, Klijn JCM, Rubens RD, et al: "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Cooperative Group phase III trial (10808). Eur J Cancer 27:966-970, 1991
78. Habeshaw T, Paul J, Jones R, et al: Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: The results of a randomized trial. J Clin Oncol 9:295-304, 1991
79. Muss HB, Case LD, Richards F, et al: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med 325:1342-1348, 1991
80. Ejlertsen B, Pfeiffer P, Pedersen D, et al: Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 29A:527-531, 1993
81. Focan C, Andrein JM, Closon MTh, et al: Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 11:1253-1263, 1993
82. Ardizzoni A, Venturini M, Sertoli MR, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: A randomised study in patients with advanced breast cancer. Br J Cancer 69:385-391, 1994
83. Ceci G, Bisagni C, Cocconi G, et al: Cisplatin and VP16 in metastatic breast carcinoma as a third-line chemotherapy: A randomized study comparing low versus high doses of cisplatin. Tumori 81:241-244, 1995
84. Riccardi A, Giordano M, Brugnatelli S, et al: Different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-fluorouracil: A randomised study in advanced breast cancer. Eur J Cancer 31A:1549-1551, 1995
85. Athanassiou A: Dose intensification by using human recombinant granulocyte-macrophage colony stimulating factor in advanced breast cancer patients. Eur J Gynaecol Oncol 17:411-413, 1996
86. Bastholt L, Dalmark M, Gjedde SB, et al: Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 14:1146-1155, 1996
87. Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
88. 2) in the FEC regimen significantly increases response rates. An international randomized phase III study in metastatic breast cancer. Ann Oncol 8:155-162, 1997
89. Mattsson W: A phase III trial of treatment with tamoxifen versus treatment with high dose medroxyprogesterone-acetate in advanced postmenopausal breast cancer, in Iacobelli S, Di Marco A (eds): Role of Medroxyprogesterone in Endocrine-Related Tumors. New York, NY, Raven, 1980, pp 65-71
90. Westerberg H: Tamoxifen and fluoxymesterone in advanced breast cancer: A controlled clinical trial. Cancer Treat Rep 64:117-121, 1980
91. Beex L, Pieters G, Smals A, et al: Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rep 65:179-185, 1981
92. Ingle JN, Ahmann DL, Green SJ, et al: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304:16-21, 1981
93. Beretta G, Tabiadon D, Tedeschi L, et al: Hormonotherapy of advanced breast carcinoma: comparative evaluation of tamoxifen citrate versus medroxyprogesterone acetate, in Iacobelli S (ed): The Role of Tamoxifen in Breast Cancer. New York, NY, Raven, 1982, pp 113-120
94. Harvey HA, Lipton A, White DS, et al: Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer. Cancer Res 42:3451s-3453s, 1982 (suppl)
95. Ingle JN, Ahmann DL, Green SJ, et al: Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol 5:155-160, 1982
96. Lipton A, Harvey HA, Santen RJ, et al: Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res 42:3434s-3436s, 1982 (suppl)
97. Pannuti F, Martoni A, Fruet F, et al: Oral high dose medroxyprogesterone acetate versus tamoxifen in postmenopausal patients with advanced breast cancer, in Iacobelli S (ed): The Role of Tamoxifen in Breast Cancer. New York, NY, Raven, 1982, pp 85-92
98. Smith IE, Harris AL, Morgan M, et al: Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res 42:3430s-3433s, 1982 (suppl)
99. Allegra JC, Bertino J, Bonomi P, et al: Metastatic breast cancer: Preliminary results with oral hormonal therapy. Semin Oncol 12:61-64, 1985
100. Matelski H, Huberman M, Zipoli T, et al: Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer. Am J Clin Oncol 8:128-133, 1985
101. Morgan LR: Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients. Semin Oncol 12:43-47, 1985 (suppl 1)
102. Buchanan RB, Blamey RW, Durrant KR, et al: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4:1326-1330, 1986
103. Ettinger DS, Allegra J, Bertino JR, et al: Megestrol acetate v tamoxifen in advanced breast cancer: Correlation of hormone receptor and response. Semin Oncol 13:9-14, 1986 (suppl 4)
104. Gockerman JP, Spremulli EN, Raney M, et al: Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: A Southeastern Cancer Study Group trial. Cancer Treat Rep 70:1199-1203, 1986
105. Ingle JN, Krook JE, Green SJ, et al: Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4:178-185, 1986
106. Van Veelen H, Willemse PHB, Tjabbes T: Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer. Cancer 58:7-13, 1986
107. Kellokumpu-Lehtinen P, Huovinen R, Johansson R: Hormonal treatment of advanced breast cancer. A randomized trial of tamoxifen versus nandrolone decanoate. Cancer 60:2376-2381, 1987
108. Alonso-Munoz MC, Ojeda-Gonzalez MB, Beltran-Fabregat M, et al: Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer. Oncology 45:350-353, 1988
109. Muss HB, Wells HB, Paschold EH, et al: Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis - A phase III trial of the Piedmont Oncology Association. J Clin Oncol 6:1098-1106, 1988
110. Paterson AHG, Hanson J, Pritchard KI, et al: Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. Semin Oncol 17:52-62, 1990
111. Castiglione-Gertsch M, Pampallona S, Varini M, et al: Primary endocrine therapy for advanced breast cancer: To start with tamoxifen or with medroxyprogesterone acetate? Ann Oncol 4:735-740, 1993
112. Gill PG, Gebski V, Snyder R, et al: Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann Oncol 4:741-744, 1993
113. Pronzato P, Bertelli G, Rosso M: A randomized trial on tamoxifen continuation during second-line hormone therapy in breast cancer. Ann NY Acad Sci 698:357-361, 1993
114. Stenbygaard LE, Herrstedt J, Thomsen JF, et al: Toremifene and tamoxifen in advanced breast cancer - A double-blind cross-over trial. Breast Cancer Res Treat 25:57-63, 1993
115. Boccardo F, Rubagotti A, Perrotta A, et al: Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: Results of a multicentric Italian study. Ann Oncol 5:337-342, 1994
116. Gale KE, Andersen JW, Tormey DC, et al: Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group phase III trial comparing aminoglutethimide to tamoxifen. Cancer 73:354-361, 1994
117. Muss HB, Case LD, Atkins JN, et al: Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: A Piedmont Oncology Association study. J Clin Oncol 12:1630-1638, 1994
118. Perez Carrion R, Alberola Candel V, Calabresi F, et al: Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 5:S19-S24, 1994 (suppl 7)
119. Hayes DF, Van Zyl JA, Hacking A, et al: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13:2556-2566, 1995
120. Jonat W, Kaufmann M, Blarney RW, et al: A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer 31A:137-142, 1995
121. Falkson CI, Falkson HC: A randomised study of CGS-16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. Ann Oncol 7:465-469, 1996
122. Stuart NSA, Warwick J, Blackledge GRP, et al: A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer. Eur J Cancer 32A:1888-1892, 1996
123. Thurlimann B, Beretta K, Bacchi M, et al: First-line fadrozole HCI (CGS-16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 7:471-479, 1996
124. Mouridsen HT, Ellemann K, Mattsson W, et al: Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep 63:171-175, 1979
125. Mouridsen HT, Palshof T, Rose C: Therapeutic effect of tamoxifen alone versus tamoxifen in combination with gestagen and oestrogen in advanced breast cancer. Recent Results Cancer Res 71:169-177, 1980
126. Corkery J, Leonard RCF, Craig Henderson I, et al: Tamoxifen and aminoglutethimide in advanced breast cancer. Cancer Res 42:3409s-3414s, 1982 (suppl)
127. Powles TJ, Gordon C, Coombe RC: Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone. Cancer Res 42:3458s-3460s, 1982 (suppl)
128. Tormey DC, Lippman ME, Edwards BK, et al: Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 98:139-144, 1983
129. Pouillart P, Jouve M, Palangie T, et al: Disseminated breast cancer: Sequential administration of tamoxifen and medroxyprogesterone acetate. Results of a controlled trial, in Iacobelli S, Di Marco A (eds): Role of Medroxyprogesterone in Endocrine-Related Tumors, vol 3. New York, NY, Raven, 1984, pp 141-155
130. Powles TJ, Ashley S, Ford HT, et al: Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. Lancet 1:1369-1373, 1984
131. Heinonen E, Alanko A, Grohn P, et al: Nandrolone decanoate added to tamoxifen in the treatment of advanced breast cancer. Breast Cancer Res Treat 5:75-80, 1985
132. Milsted R, Habeshaw T, Kaye S, et al: A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer. Cancer Chemother Pharmacol 14:272-273, 1985
133. Ingle JN, Green SJ, Ahmann DL, et al: Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol 4:958-964, 1986
134. Rose C, Kamby C, Mouridsen HT, et al: Combined endocrine treament of postmenopausal patients with advanced breast cancer. Breast Cancer Res Treat 7:45-50, 1986 (suppl)
135. Bonneterre J, Mauriac L, Weber B, et al: Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: Results of a double blind multicentre clinical trial. Eur J Cancer Clin Oncol 24:1851-1853, 1988
136. Rubens RD, Tinson CL, Coleman RE, et al: Prednisolone improves the response to primary endocrine treatment for advanced breast cancer. Br J Cancer 58:626-630, 1988
137. De Lena M, Tommasi S, Schittulli F, et al: Sequential alternate administration of tamoxifen and medroxyprogesterone acetate in advanced breast cancer: Clinical-biological randomized study. Tumori 76:190-195, 1990
138. Gundersen S, Kvinnsland S, Lundgren S, et al: Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 17:45-50, 1990
139. Beltran M, Alonso MC, Ojeda MB, et al: Alternating sequential endocrine therapy: tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients. Ann Oncol 2:495-499, 1991
140. Ingle JN, Mailliard JA, Schaid DJ, et al: A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. Cancer 68:34-39, 1991
141. Ingle JN, Twito DI, Schaid DJ, et al: Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer 67:886-891, 1991
142. Bishop JF, Smith JG, Jeal PN, et al: The effect of danazol on tumour control and weight loss in patients on tamoxifen therapy for advanced breast cancer: A randomised double-blind placebo controlled trial. Eur J Cancer 29A:814-818, 1993
143. Crawford DJ, George WD, Smith DC, et al: Cyclic sequential endocrine therapy for advanced breast cancer using a combination of tamoxifen and megestrol acetate. Oncology 51:13-18, 1994 (suppl 1)
144. Izuo M, Yoshida M, Tominaga T, et al: A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancer. Cancer 56:2576-2579, 1985
145. Jakobsen A, Frederiksen PL, Moller KA, et al: Medroxyprogesterone acetate and prednisone in advanced breast cancer. Eur J Cancer Clin Oncol 22:1067-1072, 1986
146. Canney PA, Priestman TJ, Griffiths T, et al: Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma. J Natl Cancer Inst 80:1147-1151, 1988
147. Willemse PHB, van der Ploeg E, Sleijfer DT, et al: A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. Eur J Cancer 26:337-343, 1990
148. Martoni A, Longhi A, Canova N, et al: High-dose medroxyprogesterone acetate versus oophorectomy as first-line therapy of advanced breast cancer in premenopausal patients. Oncology 48:1-6, 1991
149. Garcia-Giralt E, Ayme Y, Carton M, et al: Second and third line hormonotherapy in advanced post-menopausal breast cancer: A multi-center randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Res Treat 24:139-145, 1992
150. Samonis G, Margioris AN, Bafaloukos D, et al: Prospective randomized study of aminoglutethimide (AG) versus medroxyprogesterone acetate (MPA) versus AG+MPA in generalized breast cancer. Oncology 51:411-415, 1994
151. Lundgren S, Gundersen S, Klepp R, et al: Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat 14:201-206, 1989
152. Mercer PM, Ebbs SR, Fraser SCA, et al: Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer. Eur J Surg Oncol 19:254-258, 1993
153. Buzdar A, Jonat W, Howell A, et al: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. J Clin Oncol 14:2000-2011, 1996
154. Buzdar AU, Smith R, Vogel C, et al: Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma. Cancer 77:2503-2513, 1996
155. Thurlimann B, Castiglione M, Hsu-Schmitz SF, et al: Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomized cross over trial of second-line hormonal treatment (SAKK 20/90). Eur J Cancer 33:1017-1024, 1997
156. Carter AC, Sedransk N, Kelley RM, et al: Diethylstilbestrol: Recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA 237:2079-2085, 1977
157. Robustelli Della Cuna G, Calciati A, Strada MRB, et al: High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: A dose-response evaluation. Tumori 64:143-149, 1978
158. Pannuti F, Martoni A, Di Marco AR, et al: Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer. Eur J Cancer 15:593-601, 1979
159. Bratherton DG, Brown CH, Buchanan R, et al: A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer 50:199-205, 1984
160. Cavalli F, Goldhirsch A, Jungi F, et al: Randomized trial of low-versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients wth advanced breast cancer. J Clin Oncol 2:414-419, 1984
161. Bonneterre J, Coppens H, Mauriac L, et al: Aminoglutethimide in advanced breast cancer: Clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day. Eur J Cancer Clin Oncol 21:1153-1158, 1985
162. Gallagher CJ, Cairnduff F, Smith IE: High dose versus low dose medroxyprogesterone acetate: A randomized trial in advanced breast cancer. Eur J Cancer Clin Oncol 23:1895-1900, 1987
163. Bruning PF, Bonfrer JMG, Hart AAM, et al: Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer. Eur J Cancer Clin Oncol 25:369-376, 1989
164. Muss HB, Case LD, Capizzi RL, et al: High- versus standard-dose megestrol acetate in women with advanced breast cancer: A phase III trial of the Piedmont Oncology Association. J Clin Oncol 8:1797-1805, 1990
165. Spooner D, Fairlamb D, Fermont D, et al: A multicentre trial to compare a loading dose regimen of tamoxifen ('Nolvadex') with conventional dosing in the treatment of advanced breast cancer. Clin Oncol 3:133-136, 1991
166. Raats JI, Falkson G, Falkson HC: A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. J Clin Oncol 10:111-116, 1992
167. Robustelli Della Cuna G, Pannuti F, Martoni A, et al: Aminoglutethimide in advanced breast cancer: Prospective, randomized comparison of two dose levels. Anticancer Res 13:2367-2372, 1993
168. Bajetta E, Zilembo N, Buzzoni R, et al: Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer. Br J Cancer 70:145-150, 1994
169. Rauschning W, Pritchard KI: Droloxifene, a new antiestrogen: Its role in metastatic breast cancer. Breast Cancer Res Treat 31:83-94, 1994
170. Clinton OP, Priestman TJ, Latief TN, et al: A prospective randomized trial to evaluate different oral dose regimens of medroxyprogesterone acetate in women with advanced breast cancer. Clin Oncol 7:251-256, 1995
171. Bonnefoi HR, Smith IE, Dowsett M, et al: Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer. Br J Cancer 73:539-542, 1996
172. Miller AA, Lipton A, Henderson IC, et al: Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma. Cancer 78:789-793, 1996
173. Bajetta E, Zilembo N, Barni S, et al.: A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: Endocrine and clinical results. Ann Oncol 8:649-654, 1997
174. Ingle JN, Jonhson PA, Suman VJ, et al: A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer 80:218-224, 1997
175. Brunner KW, Sonntag RW, Alberto P, et al: Combined chemo- and hormonal therapy in advanced breast cancer. Cancer 39:2923-2933, 1977
176. Rubens RD, Begent RHJ, Knight RK, et al: Combined cytotoxic and progestogen therapy for advanced breast cancer. Cancer 42:1680-1686, 1978
177. Lloyd RE, Jones SE, Salmon SE: Comparative trial of low-dose Adriamycin plus cyclophosphamide with or without additive hormonal therapy in advanced breast cancer. Cancer 43:60-65, 1979
178. Tormey DC, Falkson G, Crowley J, et al: Dibromodulcitol and Adriamycin ± tamoxifen in advanced breast cancer. Am J Clin Oncol 5:33-39, 1982
179. Cocconi G, De Lisi V, Boni C, et al: Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study. Cancer 51:581-588, 1983
180. Lippman ME, Cassidy J, Wesley M, et al: A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization. J Clin Oncol 2:28-36, 1984
181. Boccardo F, Rubagotti A, Rosso R, et al: Chemotherapy with or without tamoxifen in postmenopausal patients with late breast cancer. A randomized study. J Steroid Biochem 8:275-282, 1985
182. CMEA Cooperative Treatment Group: Clinical controlled trial in advanced breast cancer: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen). Neoplasma 32:381-387, 1985
183. Kiang DT, Gay J, Goldman A, et al: A randomized trial of chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 313:1241-1246, 1985
184. Krook JE, Ingle JN, Green SJ, et al: Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer. Cancer Treat Rep 69:355-361, 1985
185. Mouridsen HT, Rose C, Engelsman E, et al: Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen. Eur J Cancer Clin Oncol 21:291-299, 1985
186. Viladiu P, Alonso MC, Avella A, et al: Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial. Cancer 56:2745-2750, 1985
187. Australian and New Zealand Breast Cancer Trials Group: A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol 4:186-193, 1986
188. Conte PF, Pronzato P, Rubagotti A, et al: Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: Results of a randomized cooperative trial. J Clin Oncol 5:339-347, 1987
189. Perry MC, Kardinal CG, Korzun AH, et al: Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081. J Clin Oncol 5:1534-1545, 1987
190. Elomaa I, Blomqvist C, Rissanen P, et al: Weekly low-dose doxorubicin with or without high-dose medroxyprogesterone acetate as secondary treatment in metastatic breast cancer - A randomized trial. Acta Oncol 27:297-299, 1988
191. Gundersen S, Kvinnsland S, Klepp O, et al: Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Eur J Cancer 28:390-394, 1992
192. Falkson CI, Falkson G, Falkson CB, et al: A randomized trial of mitomycin-C (M) versus mitomycin-C plus high-dose medroxyprogesterone acetate (MMPA) in the treatment of patients with advanced breast cancer. Am J Clin Oncol 16:14-17, 1993
193. Gundersen S, Hannisdal E, Lundgren S, et al: Weekly doxorubicin with or without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer. A randomised study. Eur J Cancer 30A:1775-1778, 1994
194. Ingle JN, Foley JF, Mailliard JA, et al: Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer. Cancer 73:2337-2343, 1994
195. Tominaga T, Abe O, Ohshima A, et al: Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer. Eur J Cancer 30A:959-964, 1994
196. Abe O, Asaishi K, Izuo M, et al: Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system. Surg Today 25:701-710, 1995
197. Falkson G, Holcroft C, Gelman RS, et al: Ten-year follow-up study of premenopausal women with metastatic breast cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 13:1453-1458, 1995
198. Tashiro H, Nomura Y: Mitomycin C, methotrexate, and vincnstine with medroxyprogesterone acetate or prednisolone for doxorubicin resistant advanced breast cancer - A randomized control study. Anticancer Res 15:2229-2238, 1995
199. Conte PF, Baldini E, Gardin G, et al: Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 7:487-490, 1996
200. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15, 71-85, 1992
201. Coates A, Gebski V, Signorini D, et al: Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. J Clin Oncol 10:1833-1838, 1992
202. Chlebowski RT, Lillington LM: A decade of breast cancer clinical investigation: Results as reported in the Program/Proceedings of the American Society of Clinical Oncology. J Clin Oncol 12:1789-1795, 1994
203. Hortobagyi GN: High-dose chemotherapy is not an established treatment for breast cancer. ASCO Educational Book, Spring 1995, pp 341-346
204. Kornblith AB, Hollis DR, Zuckerman E, et al: Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. J Clin Oncol 11:2081-2089, 1993
205. Richards MA, Hopwood P, Ramirez AJ, et al: Doxorubicin in advanced breast cancer: Influence of schedule on response, survival and quality of life. Eur J Cancer 28A:1023-1028, 1992
206. Batel-Copel LM, Kornblith AB, Batel PC, et al: Do oncologists have an increasing interest in the quality of life of their patients? A literature review of the last 15 years. Eur J Cancer 33:29-32, 1997
207. Torfs K: Economic evaluation of cancer treatment strategies. Eur J Cancer 33:S35-S39, 1997 (suppl 4)
208. Stewart LA, Parmar MKB: Meta-analysis of the literature or of individual patient data: Is there a difference? Lancet 341:418-422, 1993
209. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2489, 1995
210. Kennedy MJ: High-dose chemotherapy of breast cancer: Is the question answered? J Clin Oncol 13:2477-2479, 1995
211. Goldman L, Loscalzo A: Fate of cardiology research originally published in abstract form. N Engl J Med 303:255-259, 1980
212. Gregoire G, Derderian F, Le Lorier J: Selecting the language of the publications included in a meta-analysis: Is there a Tower of Babel bias? J Clin Epidemiol 48:159-163, 1995
213. Tinazzi A, Carinci F, Torri V: Graphical aspect of meta-analysis using SAS/GRAPH and its specific annotate language. A set of specific macro routines to perform and display result of meta-analysis. SEUGI '96. SAS European User Group International, Hamburg, Germany, June 11-14, 1996 (CD-ROM version)